PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 274, Issue 5 37-5, 1998, Pages

  Filipsson, Karin ^a   Pacini, Giovanni ^b   Scheurink, Anton J W ^c   Ahrén, Bo ^a,d  

^a LUND UNIVERSITY   (Sweden)

^b Inst of Syst Sci and Biomed Eng   (Italy)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Glucose effectiveness; Minimal model; Pituitary adenylate cyclase activating polypeptide

Indexed keywords

ADRENALIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; INSULIN;

ADRENALIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031832016     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1998.274.5.e834     Document Type: Article

References (36)

1. Ader, M., G. Pacini, Y. J. Yang, and R. N. Bergman. Importance of glucose per se to intravenous glucose tolerance: comparison of the minimal-model prediction with direct measurements. Diabetes 34: 1092-1103, 1985.
2. Af Klinteberg, K., A. N. Al-Amin, J. Hannibal, F. Sundler, and B. Ahrén. Effects and localization of the neuropeptide PACAP and PACAP receptor expression in insulin producing tissues (Abstract). Diabetologia 39, Suppl. 1: A71, 1996.
3. Af Klinteberg, K., S. Karlsson, and B. Ahrén. Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells. Endocrinology 137: 2791-2798, 1996.
4. Ahrén, B., and I. Lundquist. Effects of selective and nonselective β-adrenergic agents on insulin secretion in vivo. Eur. J. Pharmacol. 71: 93-104, 1981.
5. Ahrén, B., and G. Pacini. Impaired adaptation of first phase insulin secretion in postmenopausal women with glucose intolerance. Am. J. Physiol. 273 (Endocrinol. Metab. 36): E701-E707, 1997.
6. Arimura, A., and S. Shioda. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16: 53-88, 1995.
7. Balkan, B., and B. E. Dunning. Muscarinic stimulation maintains in vivo insulin secretion in response to glucose after prolonged hyperglycemia. Am. J. Physiol. 268 (Regulatory Integrative Comp. Physiol. 37): R475-R479, 1995.
8. Bergman, R. N. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38: 1512-1527, 1989
9. Bergman, R. N., L. S. Phillips, and C. Cobelli. Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin. Invest. 68: 1456-1467, 1981.
10. Bertrand, G., R. Puech, Y. Maissonnasse, J. Bockaert, and M. M. Loubatières-Mariani. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rats. Br. J. Pharmacol. 117: 764-770, 1996.
11. Best, J. D., S. E. Kahn, M. Ader, R. M. Watanabe, T.-C. Ni, and R. N. Bergman. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19: 1018-1030, 1996.
12. D'Alessio, D. A., S. E. Kahn, C. R. Leusner, and J. W. Ensinck. Glucagon-like peptide 1 enhances glucose tolerance by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 93: 2263-2266, 1994.
13. Filipsson, K., K. Tornoe, J. Hoist, and B. Ahrén. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates insulin and glucagon secretion in humans. J. Clin. Endocrinol. Metab. 82: 3093-3098, 1997.
14. Finegood, D. T. Application of the minimal model of glucose kinetics. In: The Minimal Model Approach and Determinants of Glucose Tolerance, edited by R. N. Bergman and J. C. Lovejoy. Baton Rouge, LA: Louisiana State Univ. Press, 1997, p. 51-122.
15. Fridolf, T., F. Sundler, and B. Ahrén. Pituitary adenylate cyclase activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. Cell Tissue Res. 269: 275-279, 1992.
16. Gutniak, M. K., H. Larsson, S. J. Heiber, O. T. Juneskans, J. J. Holst, and B. Ahrén. Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19: 843-848, 1996.
17. Inagaki, N., H. Yoshida, M. Mizuta, N. Mizuno, Y. Fujii, T. Gonoi, J. Miyazaki, and S. Seino. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. USA 91: 2679-2683, 1994.
18. Kahn, S. E., R. N. Bergman, M. W. Schwartz, G. J. Taborsky, Jr., and D. Porte, Jr. Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am. J. Physiol. 262 (Endocrinol. Metab. 25): E518-R523, 1992.
19. Kahn, S. E., L. J. Klaff, M. W. Schwartz, J. C. Beard, R. N. Bergman, G. J. Taborsky, Jr., and D. Porte, Jr. Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J. Clin. Endocrinol. Metab. 71: 994-1002, 1990.
20. Kahn, S. E., R. L. Prigeon, D. K. McCulloch, E. J. Boyko, R. N. Bergman, M. W. Schwartz, J. L. Neifing, W. K. Ward, J. C. Beard, J. P. Palmer, and D. Porte, Jr. The contribution of insulin independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43: 587-592, 1993.
21. Kawai, K., C. Yokota, S. Ohashi, K. Isobe, S. Suzuki, T. Nakai, and K. Yamashita. Pituitary adenylate cyclase-activating polypeptide: effects on pancreatic-adrenal hormone secretion and glucose-lipid metabolism in normal conscious dogs. Metabolism 43: 739-744, 1994.
22. 2+. Mol. Pharmacol. 50: 1047-1054, 1996.
23. Laury, M. C., F. Takao, D. Bailbe, L. Penicaud, B. Portha, and A. Ktorza. Differential effects of prolonged hyperglycemia on in vivo and in vitro insulin secretion in rats. Endocrinology 128: 2526-2533, 1991.
24. Lönnroth, P., J. I. Davies, I. Lönnroth, and U. Smith. The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic AMP-dependent and -independent mechanisms. Biochem. J. 243: 798-795, 1987.
25. Meguid, M. M., F. Aun, J. S. Soeldner, D. A. Albertson, and C. M. Boyden. Insulin half-life in man after trauma. Surgery 89: 650-653, 1981.
26. Miyata, A., A. Arimura, R. R. Dahl, N. Minamino, A. Uehara, L. Jiang, M. D. Culler, and D. H. Coy. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164: 567-574, 1989.
27. Miyata, A., L. Jiang, R. R. Dahl, C. Kitada, K. Kubo, M. Fujino, N. Minamino, and A. Arimura. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 170: 643-648, 1990.
28. Scheurink, A., and S. Ritter. Sympathoadrenal responses to glucoprivation and lipoprivation in rats. Physiol. Behav. 53: 995-1000, 1993.
29. Sekiguchi, Y., K. Kasai, K. Hasegawa, Y. Suzuki, and S. Shimoda. Glycogenolytic activity of pituitary adenylate cyelase activating polypeptide (PACAP) in vivo and in vitro. Life Sci. 55: 1219-1228, 1994.
30. Söderström, T., and P. Stoica. System Identification. New York: Prentice-Hall, 1989.
31. Steil, G. M., A. Volund, S. E. Kahn, and R. N. Bergman. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Diabetes 42: 250-256, 1993.
32. Wang, P. R., and Y W. Chien. Day-night differences in the kinetics and dynamics of insulin: diabetic versus normal Yucatan minipigs. Chronobiol. Int. 13: 213-225, 1996.
33. Wei, Y., and S. Mojsov. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J. Neuroendocrinol. 8: 811-818, 1996.
34. Yada, T., M. Sakurada, K. Ihada, M. Nakata, F. Murata, A. Arimura, and M. Kikuchi. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet β-cells. J. Biol. Chem. 269: 1290-1293, 1994.
35. Yokota, C., K. Kawai, S. Ohashi, Y Watanabe, S. Suzuki, and K. Yamashita. Stimulatory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on insulin and glucagon release from the isolated rat pancreas. Acta Endocrinol. 129: 473-479, 1993.
36. Yokota, C., K. Kawai, S. Ohashi, Y Watanabe, and K. Yamashita. PACAP stimulates glucose output from the perfused rat liver. Peptides 16: 55-60, 1995.